Fraiser Kansteiner is a staff writer at Fierce Pharma. He covers key topics in medicine and healthcare, including pharmaceutical manufacturing, drug delivery, and the impacts of COVID-19, with a focus on the intersection of business and health. Fraiser's work has been featured in NewsBreak, Biotech, and Fierce Pharma.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Fraiser Kansteiner's coverage primarily revolves around the healthcare and pharmaceutical industry, with a focus on regulatory announcements, press releases, and data citations. To effectively reach out to Fraiser, consider providing insights into pharmaceutical industry trends, drug developments or FDA regulations. Sources with access to unpublished data or exclusive information about pivotal events within the healthcare sector may be of particular interest to him.
Since Fraiser does not specify any geographic focus in his articles, it is likely that he covers global pharmaceutical news and would be interested in international perspectives on key issues within the industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Fraiser Kansteiner
As multiple large drugmakers look to navigate trade turbulence by pumping billions of dollars into their U.S.
By: Fraiser Kansteiner
Just as Eli Lilly appeared to be gaining an edge over its metabolic medicine rival Novo Nordisk in the U.S.
By: Fraiser Kansteiner
Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site.
By: Fraiser Kansteiner
After revealing in February plans to save $2 billion more on top of a previously disclosed cost-cutting initiative, Bristol Myers Squibb is conducting another round of job cuts in the Garden State.
By: Fraiser Kansteiner
Monday, Bristol Myers Squibb helmsman Chris Boerner joined a growing list of life sciences leaders announcing major U.S. investments in the face of potential pharmaceutical import tariffs.
By: Fraiser Kansteiner
In the wake of mass restructuring efforts across the Department of Health and Human Services, the FDA has missed yet another approval decision target date.
By: Fraiser Kansteiner
With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in the realm of rare disease.
By: Fraiser Kansteiner
Despite holding the lead with its complement inhibitor Syfovre, Apellis Pharmaceuticals is discovering that the geographic atrophy market is a tough nut to crack.
By: Fraiser Kansteiner
It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit.
(833) 317-6278 
